Cantor Fitzgerald Estimates MLTX FY2025 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of MoonLake Immunotherapeutics in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal anticipates that the company will post earnings of ($1.91) per share for the year. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.75) per share.

Several other research firms have also recently commented on MLTX. The Goldman Sachs Group raised MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and raised their target price for the stock from $62.00 to $82.00 in a research note on Friday, January 17th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of MoonLake Immunotherapeutics in a research note on Friday, January 10th. Finally, Wedbush reaffirmed an “outperform” rating and set a $73.00 target price (down previously from $92.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, MoonLake Immunotherapeutics currently has an average rating of “Buy” and an average price target of $84.29.

MoonLake Immunotherapeutics Trading Up 2.8 %

NASDAQ MLTX opened at $47.11 on Thursday. The business’s 50-day moving average price is $51.23 and its two-hundred day moving average price is $49.08. MoonLake Immunotherapeutics has a 12 month low of $37.55 and a 12 month high of $64.98.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.12). During the same quarter in the previous year, the company posted ($0.18) earnings per share.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. US Bancorp DE bought a new position in shares of MoonLake Immunotherapeutics in the third quarter valued at approximately $44,000. Quarry LP increased its position in MoonLake Immunotherapeutics by 172.7% in the second quarter. Quarry LP now owns 3,000 shares of the company’s stock worth $132,000 after buying an additional 1,900 shares during the last quarter. Barclays PLC increased its position in MoonLake Immunotherapeutics by 1,269.2% in the third quarter. Barclays PLC now owns 5,641 shares of the company’s stock worth $283,000 after buying an additional 5,229 shares during the last quarter. Handelsbanken Fonder AB grew its position in shares of MoonLake Immunotherapeutics by 26.2% in the third quarter. Handelsbanken Fonder AB now owns 13,000 shares of the company’s stock valued at $655,000 after purchasing an additional 2,700 shares in the last quarter. Finally, AlphaCentric Advisors LLC bought a new stake in MoonLake Immunotherapeutics during the third quarter valued at $706,000. Institutional investors own 93.85% of the company’s stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.